Strategic Partnering
Strategic Partnering
Inventage Lab pursues strategic partnerships with global pharmaceutical and biotech companies, centered on our DrugFluidic® long-acting injectable platform based on microfluidic technology and the BioFluidic™ high-concentration bio-formulation platform. DrugFluidic® provides long-acting formulations with adjustable dosing intervals from 1 to 6 months depending on drug properties,
while BioFluidic™ enables formulation differentiation by realizing high-dose biopharmaceuticals as stable subcutaneous injections. Through out-licensing of in-house pipelines and joint research based on feasibility studies, we have established a flexible collaboration structure from research to commercialization, minimizing development risks for partners while expanding technology and product value together.
We focus on two main types of collaboration:
In-house Pipeline Out-Licensing
In-house Pipeline Out-Licensing
Inventage Lab out-licenses differentiated formulation pipelines developed based on the DrugFluidic® platform to global human and veterinary pharmaceutical companies. Our in-house pipeline offers the following core values:
Precise drug release control based on monodisperse microspheres and uniform formulation structure
Improved medication adherence and therapeutic effect through reduced administration frequency
Rapid and stable scale-up from research to pilot to GMP production
Reliable clinical and commercial production capabilities based on sterile GMP facilities
Our out-licensing pipeline covers various therapeutic areas including metabolic diseases, CNS, dermatology, rare diseases, and veterinary medicine.
DDS Platform based Formulation Collaboration
DDS Platform based Formulation Collaboration
Formulation Collaboration is a joint research model that creates new formulation value by applying Inventage Lab’s DrugFluidic® or BioFluidic™ platform to a partner’s API. We proceed with phased and efficient collaboration aiming to develop long-acting injectables or high-concentration subcutaneous formulations.
Initial formulation screening and physicochemical/release characteristic optimization
In vivo PK evaluation and release profile design
Lab → Pilot Scale prototype production
Technology transfer and expansion to GMP manufacturing processes
Through this, partners can achieve formulation differentiation of their assets, mitigation of development risks, lifecycle extension, and establishment of First-in-Class or Best-in-Class strategies.
